Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
I know, that buy dildos online is cheaper.
Popular Articles

Daiichi Sankyo And Lilly Receive U.S. FDA Approval For Effient(TM)
Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved Effient(TM) (prasugrel) tablets for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI). PCI usually includes the placement of a stent to help keep the artery open.
drugs without prescription
A Selection Of Editorials And Opinions
The Slow, Slow Pulse Of The Deliberative Body The Washington Post
News of the day
Dartmouth Studies Influence Administration, Even In Choice Of Venue
When President Obama chose Green Bay, Wis., to talk about the need for health reform, he did so in part because the area has achieved a high level of quality, and compared with other parts of the country, succeeded in restraining health care costs, National Public Radio reports. "They"re certainly spending a lot less money, and they are providing care that is equal or better than the care that is provided in many other communities around the country," Elliot Fisher, a researcher at the Dartmouth Institute for Health Policy and Clinical Practice told NPR in an interview. NPR says: "Some of the research the administration is relying on comes from the Dartmouth Institute for Health Policy and Clinical Practice," which focuses on variations in health quality and costs around the country.
Oncology

Comprehensive Review On Sulfonylureas In The Latest Issue Of Diabetic Hypoglycemia (09 June 2009)

The latest issue of the online journal Diabetic Hypoglycemia features an authoritative review on sulfonylureas by Professor Ian Campbell, a leading expert in oral hypoglycemia therapy. Professor Campbell"s review focuses on sulfonylurea-induced hypoglycemia (SIH), which is a well-recognized side-effect of this class of therapy for type 2 diabetes. In the review he discusses the incidence of SIH, with particular reference to the different sulfonylureas. He also reflects on the morbidity and mortality seen with SIH, precipitating risk factors, treatment of SIH, and education of patients and medical staff in the prevention of SIH. This issue of Diabetic Hypoglycemia also includes a case study on recurring hypoglycemia associated with glibenclamide, by Professor Campbell. Dr Rory McCrimmon of the Editorial Board reviews the literature on blood glucose monitoring in hypoglycemia, in an editorial entitled "What we"re learning from continuous glucose monitoring". This issue of Diabetic Hypoglycemia also features an "In profile" interview with Professor Stephanie Amiel, a leading expert in the use of neuroimaging in diabetes and hypoglycemia. About the Journal Diabetic Hypoglycemia is an influential online diabetes journal. The Editorial Board of hypoglycemia experts peer review all Journal content. The Board is led by Editor-in-Chief Professor Brian Frier (Edinburgh, UK), with Associate Editors: Professor Simon Heller (Sheffield, UK), Professor Christopher Ryan (Pittsburgh, USA) and Dr Rory McCrimmon (Yale, USA). Diabetic Hypoglycemia is published three times a year, providing an interactive forum for readers to share practical knowledge and opinions on the rapidly evolving field of hypoglycemia. To explore the Diabetic Hypoglycemia website and its key features, our guided tour can be activated by clicking the following link here. Diabetic Hypoglycemia is published by ESP Bioscience. Support for the journal is provided by an unrestricted educational grant from Novo Nordisk A/S (Bagsvaerd, Denmark). ESP Bioscience


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009